All Compounds
Plain-language profiles for the compounds we cover, with practical summaries, delivery context, and links into the deeper editorial coverage.
9 compounds
Semaglutide
The most studied weight-loss peptide, with the deepest safety record and the broadest formulation range.
View compound →
Tesamorelin
A well-documented GHRH analog with one of the clearest visceral-fat angles in the broader peptide discussion.
View compound →
Tirzepatide
A dual-action incretin compound with some of the strongest average weight-loss data in current use.
View compound →
AOD-9604
A GH-fragment weight-loss compound that keeps showing up in fat-loss research and protocol-driven search demand.
View compound →
Liraglutide
The first-generation GLP-1 option with the longest real-world track record and steadier, more moderate results.
View compound →
Retatrutide
A fast-rising triple-agonist candidate with eye-catching early data and high editorial curiosity.
View compound →
Cagrilintide
A rising amylin-analog weight-loss compound that matters most in combination and comparison conversations.
View compound →
Fragment 176-191
An experimental GH-fragment compound that keeps attracting search traffic around dosage, results, and side-effect questions.
View compound →
Tesofensine
A peptide-adjacent small-molecule research drug that overlaps with high-intent weight-loss comparisons.
View compound →